Benaglutide - Shanghai Benemae Pharmaceutical
Alternative Names: BEM-014; Benaziride; HYBR-014; YE Sang ThaiLatest Information Update: 28 Jun 2021
At a glance
- Originator Shanghai Benemae Pharmaceutical
- Class Antihyperglycaemics; Obesity therapies; Peptides
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- Phase III Obesity
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (SC, Injection)
- 03 May 2018 Launched for Type-2 diabetes mellitus in China (SC)
- 03 May 2018 Phase-I clinical trials in Type-2 diabetes mellitus in USA (SC)